Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia
ABSTRACT: Objectives: In this study, we aimed to investigate vaccine effectiveness (VE) against SARS-CoV-2 infections among adolescents aged 12 to 17 years in Malaysia and examine potential VE differences after full vaccination. Methods: We consolidated data on COVID-19 testing, vaccination, and ou...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-08-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S120197122200251X |
| _version_ | 1811243311319482368 |
|---|---|
| author | Masliyana Husin Peter Seah Keng Tok Jing Lian Suah Thevesh Thevananthan Boon Hwa Tng Kalaiarasu M. Peariasamy Sheamini Sivasampu |
| author_facet | Masliyana Husin Peter Seah Keng Tok Jing Lian Suah Thevesh Thevananthan Boon Hwa Tng Kalaiarasu M. Peariasamy Sheamini Sivasampu |
| author_sort | Masliyana Husin |
| collection | DOAJ |
| description | ABSTRACT: Objectives: In this study, we aimed to investigate vaccine effectiveness (VE) against SARS-CoV-2 infections among adolescents aged 12 to 17 years in Malaysia and examine potential VE differences after full vaccination. Methods: We consolidated data on COVID-19 testing, vaccination, and outcomes for all public school-going adolescents in Malaysia from September 1, 2021, to December 31, 2021, and estimated the VE against SARS-CoV-2 infections during this period. Cases were defined as positive tests, either by reverse transcriptase- PCR (RT-PCR) or rapid antigen (RTK-Ag) testing, while controls were negative tests. Secondarily, we restricted the analysis to all tests performed in December 2021 and compared VE by month of full vaccination. Results: A total of 175,880 eligible tests (53.4% or 93,995 RT-PCR tests) were included. After full vaccination with BNT162b2, VE against SARS-CoV-2 infections was 65.7% (95% confidence interval [CI] 64.4, 66.9) over the study period. When restricted to tests in December 2021, VEs for those fully vaccinated in September 2021, October 2021, and November 2021 were comparable (60.6% [95% CI 23.7, 81.5], 56.9% [95% CI 51.1, 62.0], and 65.7% [95% CI 59.8, 70.7] respectively). Conclusions: Among adolescents, full vaccination with BNT162b2 offered considerable protection against SARS-CoV-2 infections over at least three months without substantial evidence of waning. |
| first_indexed | 2024-04-12T14:06:19Z |
| format | Article |
| id | doaj.art-52c61041e61d49ed8b97f3178ea791c5 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-12T14:06:19Z |
| publishDate | 2022-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-52c61041e61d49ed8b97f3178ea791c52022-12-22T03:30:04ZengElsevierInternational Journal of Infectious Diseases1201-97122022-08-011215557Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in MalaysiaMasliyana Husin0Peter Seah Keng Tok1Jing Lian Suah2Thevesh Thevananthan3Boon Hwa Tng4Kalaiarasu M. Peariasamy5Sheamini Sivasampu6Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170, Malaysia; Corresponding Author(s): Masliyana Husin, Peter Seah Keng Tok Institute for Clinical Research, National Institutes of Health, Ministry of Health, Malaysia, No. 1 Jalan Setia Murni U13/52 Seksyen U13, 40170 Shah Alam, Selangor. No. Tel: 03-33647700.Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170, Malaysia; Corresponding Author(s): Masliyana Husin, Peter Seah Keng Tok Institute for Clinical Research, National Institutes of Health, Ministry of Health, Malaysia, No. 1 Jalan Setia Murni U13/52 Seksyen U13, 40170 Shah Alam, Selangor. No. Tel: 03-33647700.Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170, MalaysiaDisease Control Division, Ministry of Health Malaysia, Putrajaya, 62590, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170, MalaysiaInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170, MalaysiaABSTRACT: Objectives: In this study, we aimed to investigate vaccine effectiveness (VE) against SARS-CoV-2 infections among adolescents aged 12 to 17 years in Malaysia and examine potential VE differences after full vaccination. Methods: We consolidated data on COVID-19 testing, vaccination, and outcomes for all public school-going adolescents in Malaysia from September 1, 2021, to December 31, 2021, and estimated the VE against SARS-CoV-2 infections during this period. Cases were defined as positive tests, either by reverse transcriptase- PCR (RT-PCR) or rapid antigen (RTK-Ag) testing, while controls were negative tests. Secondarily, we restricted the analysis to all tests performed in December 2021 and compared VE by month of full vaccination. Results: A total of 175,880 eligible tests (53.4% or 93,995 RT-PCR tests) were included. After full vaccination with BNT162b2, VE against SARS-CoV-2 infections was 65.7% (95% confidence interval [CI] 64.4, 66.9) over the study period. When restricted to tests in December 2021, VEs for those fully vaccinated in September 2021, October 2021, and November 2021 were comparable (60.6% [95% CI 23.7, 81.5], 56.9% [95% CI 51.1, 62.0], and 65.7% [95% CI 59.8, 70.7] respectively). Conclusions: Among adolescents, full vaccination with BNT162b2 offered considerable protection against SARS-CoV-2 infections over at least three months without substantial evidence of waning.http://www.sciencedirect.com/science/article/pii/S120197122200251XCOVID-19 VaccinesSARS-CoV-2BNT162b2EffectivenessAdolescentMalaysia |
| spellingShingle | Masliyana Husin Peter Seah Keng Tok Jing Lian Suah Thevesh Thevananthan Boon Hwa Tng Kalaiarasu M. Peariasamy Sheamini Sivasampu Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia International Journal of Infectious Diseases COVID-19 Vaccines SARS-CoV-2 BNT162b2 Effectiveness Adolescent Malaysia |
| title | Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia |
| title_full | Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia |
| title_fullStr | Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia |
| title_full_unstemmed | Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia |
| title_short | Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia |
| title_sort | real world effectiveness of bnt162b2 vaccine against sars cov 2 infection among adolescents 12 to 17 year olds in malaysia |
| topic | COVID-19 Vaccines SARS-CoV-2 BNT162b2 Effectiveness Adolescent Malaysia |
| url | http://www.sciencedirect.com/science/article/pii/S120197122200251X |
| work_keys_str_mv | AT masliyanahusin realworldeffectivenessofbnt162b2vaccineagainstsarscov2infectionamongadolescents12to17yearoldsinmalaysia AT peterseahkengtok realworldeffectivenessofbnt162b2vaccineagainstsarscov2infectionamongadolescents12to17yearoldsinmalaysia AT jingliansuah realworldeffectivenessofbnt162b2vaccineagainstsarscov2infectionamongadolescents12to17yearoldsinmalaysia AT theveshthevananthan realworldeffectivenessofbnt162b2vaccineagainstsarscov2infectionamongadolescents12to17yearoldsinmalaysia AT boonhwatng realworldeffectivenessofbnt162b2vaccineagainstsarscov2infectionamongadolescents12to17yearoldsinmalaysia AT kalaiarasumpeariasamy realworldeffectivenessofbnt162b2vaccineagainstsarscov2infectionamongadolescents12to17yearoldsinmalaysia AT sheaminisivasampu realworldeffectivenessofbnt162b2vaccineagainstsarscov2infectionamongadolescents12to17yearoldsinmalaysia |